About Us

Steven Yatomi-Clarke

Steven took over as CEO of Prescient Therapeutics in 2016 and has overseen its progression from start-up phase. Steven manages a team in Australia and the US and has been instrumental in strategy development; licensing; initiating and managing clinical trials; fundraising and business development.
Previously, Steven had a distinguished career as an investment banker specialising in the life sciences sector, where he was consistently one of the country’s most prolific bankers, involved in primary and secondary offerings, corporate advisory and M&A assignments. In particular, Steven leveraged his combined backgrounds in science and finance to identify undervalued and unlikely opportunities and structure deals for the mutual benefit of companies and investors.
Steven holds a Bachelor of Science with an Honours Degree in Biochemistry and Molecular Biology, and a Bachelor Commerce majoring in Economics, both from the University of Melbourne. He has been a collaborator on various immunotherapy research projects.

Steve Engle

Steven Engle is CEO of CohBar, a clinical stage biotechnology company focused on the development of mitochondrial based therapeutics, an emerging class of drugs for the treatment of age-related diseases and extending healthy lifespan. Previously, he was CEO of Averigon, an advisory firm to the life science industry. Prior to that, he was Chairman and CEO of XOMA, a developer of antibody therapeutics of multiple diseases, and Chairman and CEO of La Jolla Pharmaceutical Company, which discovered the biology of B cell tolerance, developed the first B cell toleragen for lupus patients, and received an approvable letter from the FDA.
Mr. Engle served as VP of Marketing for Cygnus, a drug delivery company, where he helped gain FDA approval of and launch Nicotrol for smoking cessation. Mr. Engle is a member of the board of AROA, a developer and marketer of regenerative products, and of Author-it Software Corporation, a developer of authoring information solutions for pharmaceutical and biotechnology companies. He is a former director of industry associations, BIO, BayBio and BIOCOM.
Mr. Engle holds M.S.E.E. and B.S.E.E. degrees from the University of Texas with a focus in biomedical engineering.

Dr James Campbell

Dr James Campbell brings to Prescient a solid track record as a scientist and commercial executive. Dr. Campbell has more than 20 years of international biotechnology research, management and leadership experience and has been involved in the creation and/or transformation of multiple successful Australian and international biotechnology companies.
He is currently CEO of Patrys Limited, a company developing novel antibody therapeutics for oncology.
He was previously the Chief Financial Officer and Chief Operating Officer of Chemgenex, which was acquired by Cephalon for $230 million in 2011. His responsibilities ranged from IP management to licensing and business development and as a member of the executive team, he helped steer and transform the company from a $10 million research based entity to a company with completed clinical trials and regulatory dossiers submitted to the FDA and EMA before its $230 million sale.
Dr Campbell also has experience advising private biotechnology companies in the US and New Zealand with capital raisings and partnering negotiations.

Dr Allen Ebens

Allen Ebens, Ph.D. brings over twenty four years of drug development experience in oncology and hematology, beginning in drug discovery at Exelixis before moving to Genentech where over 11 years he worked from concept to clinic across multiple therapeutic platforms including antibodies, small molecule drugs, antibody-drug conjugates, and T cell recruiting antibodies.
Dr. Ebens was recruited from Genentech to establish oncology discovery research at Juno Therapeutics (a CAR-T pioneer), and served as Senior Director, Immune Oncology at NGM Biopharmaceuticals.
He is currently Chief Scientific Officer of Vera Therapeutics. Dr. Ebens’ scientific contributions include numerous peer-reviewed publications of original research, a significant patent portfolio, and the advancement of nine discovery projects from initial concept to clinical development for multiple targets including one marketed therapeutic. He completed his PhD at UCLA and postdoctoral training at UCSF.

Melanie Leydin

Melanie Leydin is a highly experienced CFO and Company Secretary with 25 years of experience in the accounting profession and 15 years of experience in company secretarial services

Dr Ellen Feigal

Dr Feigal is currently a Partner and Head of the Biologics practice at global life sciences advisory firm, NDA Partners LLC, where she leads efforts in designing and executing product development and regulatory strategies in the areas of cell therapies, medical imaging, hematology and oncology. She is also adjunct faculty at the Sandra Day O’Connor College of Law, Arizona State University, where she teaches FDA drug law and medical research ethics and law.

Dr Feigal was formerly Senior Vice President overseeing research and development with the California Institute of Regenerative Medicine, a world-leading research foundation working to accelerate development of new disease modifying treatments and cures for patients with chronic diseases; Executive Medical Director, Global Development at US biotech company Amgen Inc (NASDAQ: AMGN); Vice President of Clinical Sciences at the Translational Genomics Research Institute, and directed the Division of Cancer Treatment and Diagnosis at the National Cancer Institute.

Dr Feigal serves as a Board member for Xencor Inc (NASDAQ: XNCR) a biotechnology company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases. She is also a Director of NextCure (NASDAQ: NXTC) a clinical-stage biotechnology company developing new immunotherapies to treat cancer.

Dr Feigal holds an M.D. from the University of California, Davis School of Medicine. She completed an internal medicine residency at Stanford University and a hematology oncology fellowship at the University of California, San Francisco.